A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 557 shares of REGN stock, worth $414,045. This represents 0.0% of its overall portfolio holdings.

Number of Shares
557
Previous 5,354 89.6%
Holding current value
$414,045
Previous $5.63 Million 89.6%
% of portfolio
0.0%
Previous 0.03%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1024.09 - $1201.76 $4.91 Million - $5.76 Million
-4,797 Reduced 89.6%
557 $585,000
Q2 2024

Aug 14, 2024

SELL
$883.2 - $1071.19 $49.3 Million - $59.8 Million
-55,792 Reduced 91.24%
5,354 $5.63 Million
Q1 2024

May 14, 2024

SELL
$902.69 - $993.35 $44.2 Million - $48.7 Million
-48,986 Reduced 44.48%
61,146 $58.9 Million
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $38.3 Million - $43.5 Million
49,383 Added 81.29%
110,132 $96.7 Million
Q3 2023

Nov 13, 2023

SELL
$692.45 - $844.37 $27.8 Million - $33.9 Million
-40,184 Reduced 39.81%
60,749 $50 Million
Q2 2023

Aug 11, 2023

BUY
$700.03 - $830.35 $25.2 Million - $29.9 Million
36,035 Added 55.53%
100,933 $72.5 Million
Q1 2023

May 12, 2023

BUY
$680.49 - $826.97 $17.7 Million - $21.5 Million
26,017 Added 66.91%
64,898 $53.3 Million
Q4 2022

Feb 13, 2023

SELL
$705.89 - $766.39 $13.1 Million - $14.3 Million
-18,596 Reduced 32.35%
38,881 $28.1 Million
Q3 2022

Nov 10, 2022

SELL
$573.97 - $724.32 $9.43 Million - $11.9 Million
-16,423 Reduced 22.22%
57,477 $39.6 Million
Q2 2022

Aug 11, 2022

BUY
$548.35 - $738.84 $37.5 Million - $50.6 Million
68,448 Added 1255.47%
73,900 $43.7 Million
Q1 2022

May 13, 2022

SELL
$595.12 - $698.43 $1.24 Million - $1.45 Million
-2,083 Reduced 27.64%
5,452 $3.81 Million
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $61,413 - $75,819
113 Added 1.52%
7,535 $4.76 Million
Q3 2021

Nov 12, 2021

SELL
$574.03 - $680.96 $3.02 Million - $3.58 Million
-5,263 Reduced 41.49%
7,422 $4.49 Million
Q2 2021

Aug 13, 2021

BUY
$472.8 - $558.54 $6 Million - $7.09 Million
12,685 New
12,685 $7.09 Million
Q4 2019

Feb 13, 2020

SELL
$274.13 - $376.51 $16.9 Million - $23.2 Million
-61,705 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$273.46 - $318.39 $16.2 Million - $18.9 Million
59,330 Added 2498.11%
61,705 $17.1 Million
Q2 2019

Aug 13, 2019

BUY
$299.6 - $414.82 $711,550 - $985,197
2,375 New
2,375 $743,000
Q1 2019

May 14, 2019

SELL
$372.08 - $439.57 $1.8 Million - $2.13 Million
-4,842 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$335.82 - $403.04 $2.66 Million - $3.2 Million
-7,930 Reduced 62.09%
4,842 $1.81 Million
Q3 2018

Nov 13, 2018

BUY
$351.14 - $408.51 $447,001 - $520,033
1,273 Added 11.07%
12,772 $5.16 Million
Q2 2018

Aug 13, 2018

SELL
$284.6 - $344.99 $2.95 Million - $3.58 Million
-10,373 Reduced 47.43%
11,499 $0
Q1 2018

May 15, 2018

BUY
$315.82 - $393.78 $6.91 Million - $8.61 Million
21,872 New
21,872 $7.53 Million
Q4 2017

Feb 13, 2018

SELL
$358.63 - $469.95 $9.22 Million - $12.1 Million
-25,700 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$431.38 - $504.0 $11.1 Million - $13 Million
25,700
25,700 $11.5 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.